|
|
Post by papihoyos on Oct 29, 2014 9:57:28 GMT -5
If SNF can fire their CEO because he is not French enough, they can easily ignore Afrezza for the same reason. I can easily see the NIH Syndrome (Not Invented Here, thus not French enough and thus not worthy of our attention) in full operation at a place like SNF. P.S. Mark Twain, a famous Frankofhobe, would have a ball with this one. change the name to Afrezzere. Is that French enough. |
|
|
|
Post by ashiwi on Oct 29, 2014 10:05:00 GMT -5
How about that Afrezzere makes a lot of Euros for SNY? That should be French enough.
|
|
|
|
Post by rak5555 on Oct 29, 2014 10:22:19 GMT -5
Spiro thinks Al Mann should dump Hakan and replace him with Viehbacher. Of course he would have to interview so they can make certain his accent is incomprehensible. Otherwise investors might actually know what is going on. |
|
|
|
Post by trenddiver on Oct 29, 2014 10:38:40 GMT -5
For those interested in stepping in and buying some SNY, there looks to be quite a bit of long term support (long term trendline, prior resistance, 200 week Moving average) around $42.50.
Trend
|
|
|
|
Post by babaoriley on Oct 29, 2014 11:10:58 GMT -5
I sold some Nov $44 strike puts this morning. We'll see how that works out.
|
|
|
|
Post by spiro on Oct 29, 2014 12:40:53 GMT -5
Baba, it's obvious that SNY firing this Viehbacher guy is good news for MNKD. That's why MNKD is down today. If this were bad news or no news, the share price would be up. History trumps. It's funny how during the past 10 years of bungling by MNKD's management that the board can't find anyone to fire.
|
|
|
|
Post by mdcenter61 on Oct 29, 2014 13:10:13 GMT -5
If SNF can fire their CEO because he is not French enough, they can easily ignore Afrezza for the same reason. I can easily see the NIH Syndrome (Not Invented Here, thus not French enough and thus not worthy of our attention) in full operation at a place like SNF. P.S. Mark Twain, a famous Frankofhobe, would have a ball with this one.
True, but rumor is that Mannkind will change the name of product from Afrezza to Afrencha to make it more palatable for SNY Board. All good now.
|
|
|
|
Post by jpg on Oct 29, 2014 13:57:32 GMT -5
If SNF can fire their CEO because he is not French enough, they can easily ignore Afrezza for the same reason. I can easily see the NIH Syndrome (Not Invented Here, thus not French enough and thus not worthy of our attention) in full operation at a place like SNF. P.S. Mark Twain, a famous Frankofhobe, would have a ball with this one. I really doubt that this is a significant worry. If Big Pharma only sold what they invented they would all be in big trouble. Buying out or leasing out products from small baby biotech's is now part of the DNA of BP and I really doubt this will change at Sanofi. Like I said previously I presume the CEO crossed a few red lines. The shift of part of the Paris corporate headquarters over to the US seems like an obvious way to get every French politician and ENAP graduate mad as hell at you. That was asking for trouble. The possible relocation of manufacturing employment in the generic industry in France was also a big deal for the political elite of France. The way Sanofi finds good molecules to sell is, in my humble opinion, unimportant in all this. Sanofi lives and dies by diabetes. I really doubt they would mess with that at a time when the Board has really pissed off the market. JPG |
|
|
|
Post by EveningOfTheDay on Oct 29, 2014 14:32:28 GMT -5
If SNF can fire their CEO because he is not French enough, they can easily ignore Afrezza for the same reason. I can easily see the NIH Syndrome (Not Invented Here, thus not French enough and thus not worthy of our attention) in full operation at a place like SNF. P.S. Mark Twain, a famous Frankofhobe, would have a ball with this one. In my opinion, this would make little sense, since it does not reflect the reality of the industry. While in the short run I do not see the ousting of Viehbacher as something positive for Mannkind, I think the speed with what it has taken place points, perhaps, to the fact that the decision was made a while ago. This would be an interesting question to ask in the MNKD ERCC. Where you aware of the troubles facing Sanofi's CEO when you close the deal? Where any guarantees given? How do you see this affecting MNKD in the long run? |
|
|
|
Post by jpg on Oct 29, 2014 14:42:41 GMT -5
If SNF can fire their CEO because he is not French enough, they can easily ignore Afrezza for the same reason. I can easily see the NIH Syndrome (Not Invented Here, thus not French enough and thus not worthy of our attention) in full operation at a place like SNF. P.S. Mark Twain, a famous Frankofhobe, would have a ball with this one. In my opinion, this would make little sense, since it does not reflect the reality of the industry. While in the short run I do not see the ousting of Viehbacher as something positive for Mannkind, I think the speed with what it has taken place points, perhaps, to the fact that the decision was made a while ago. This would be an interesting question to ask in the MNKD ERCC. Where you aware of the troubles facing Sanofi's CEO when you close the deal? Where any guarantees given? How do you see this affecting MNKD in the long run? The decision was apparently made just after 'someone' leaked a letter from Viehbacker to the board. Immediate action for or against keeping the CEO then became urgent. I am fairly confident Mannkind will not answer any questions on this topic other then to say they do not see any change in direction of the overall diabetic strategy at Sanofi. JPG |
|
|
|
Post by EveningOfTheDay on Oct 29, 2014 14:45:19 GMT -5
I really doubt they would mess with that at a time when the Board has really pissed off the market. JPG Considering the speed with what the board have taken action, and the timing, I would not be surprised if the decision was already made a while ago. If that is the case, it is possible Sanofi has already a plan in place on how to proceed. It would also seem pretty clear that Sanofi is been watching Mannkind from before Viehbacher became CEO, and that the BD did nothing to stop the deal with MNKD, so even though in the short run we might be up for turbulent waters, I believe none of this should change much MNKD's future with Sanofi. |
|
|
|
Post by jpg on Oct 29, 2014 15:00:24 GMT -5
I really doubt they would mess with that at a time when the Board has really pissed off the market. JPG Considering the speed with what the board have taken action, and the timing, I would not be surprised if the decision was already made a while ago. If that is the case, it is possible Sanofi has already a plan in place on how to proceed. It would also seem pretty clear that Sanofi is been watching Mannkind from before Viehbacher became CEO, and that the BD did nothing to stop the deal with MNKD, so even though in the short run we might be up for turbulent waters, I believe none of this should change much MNKD's future with Sanofi. I would tend to agree with you on this. Do keep in mind that much of the board wasn't even around before Viehbacker was CEO and I personally doubt most members would directly look for small companies like MNKD. This being said, and as I posted previously, Sanofi lives and dies by their diabetic franchise so I would be extremely surprised that on top of firing their CEO they would radically change course on Afrezza. Their problem is their over dependance on one long acting insulin. Their solution is offering an all in one diabetic management su=olution and building all the studies around this. If I am right we will soon see studies using their new insulin with Afrezza trying to prove superiority in management (better 'peak and valley' glucose as a primary and HbA1C as a secondary outcome). Once you convincingly get this Sanofi will own the diabetic space. It can't happen without Afrezza though. Using real time (or every 5-10 minute) glucose monitoring would make this extremely elegant. You could have an 'artificial pancreas' on the very cheap that way... JPG |
|
|
|
Post by kc on Oct 29, 2014 15:36:04 GMT -5
I don't see it as a major bump in the road as the entire board had to be in agreement to partner with MannKind. There was an article published that stated Weinberg would be involved with the Launch in November 20, 2014.
Attachment Deleted |
|
|
|
Post by jpg on Oct 29, 2014 15:58:23 GMT -5
I don't see it as a major bump in the road as the entire board had to be in agreement to partner with MannKind. There was an article published that stated Weinberg would be involved with the Launch in November 20, 2014.
It seems logical that after doing something so radical (in the context of where Sanofi was 6 years ago and now) as to fire their 'saviour' CEO and doing it so badly that they will follow the predetermined roadmap very carefully. Overall this could be a short to medium term positive for Afrezza. Weinberg and the board now 'own' whatever happens to Sanofi in the coming months and until they find a new CEO. That Weinberg let his name be publicly attached to Afrezza is, to me anyway, a big deal. JPG |
|
|
|
Post by jpg on Oct 29, 2014 16:13:32 GMT -5
|
|
